A settlement valued at $8.34 billion was reached between Purdue Pharmaand the Justice Department, which required the drug company to plead guilty to three felonies related to its marketing and distribution of OxyContin, according to the Wall Street Journal.

Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global Covid-19 pandemic.

Federal health regulators decided to allow the resumption of the U.S. trial of a leading Covid-19 vaccine candidate from AstraZeneca Plc and the University of Oxford, the Wall Street Journal reported, citing a person familiar with the matter and materials reviewed by it.

Moderna Inc. Chief Executive Officer Stéphane Bancel expects interim results from the company’s Covid-19 vaccine trial in November and that the U.S government could give an emergency use nod in December, the Wall Street Journal reported.

Becton Dickinson is investigating reports from U.S. nursing homes that the company’s rapid coronavirus testing equipment is producing false-positive results.

Gilead Sciences Inc. is nearing a deal to buy biopharmaceutical company Immunomedics Inc. for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.

U.S. drugmaker Merck & Co. Inc. began recruiting participants to the company’s early-stage Covid-19 vaccine study, according to the government database clinicaltrials.gov.

Several Covid-19 vaccine developers, including Pfizer Inc., Johnson & Johnson and Moderna Inc., plan to issue a public pledge not to seek government approval until their vaccine candidates are proven to be safe and effective, the Wall Street Journal reported.

Johnson & Johnson aims to test the company’s experimental coronavirus vaccine in up to 60,000 volunteers in a late-stage trial scheduled to start in September, according to a U.S. government database of clinical trials.

A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.